Live Breaking News & Updates on Biologics License Application

Stay updated with breaking news from Biologics license application. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Opthea Successfully Completes Placement and Institutional

Fully underwritten Retail Entitlement Offer to raise a further approximately A$55.9m (US$36.9m1) will open on 19 June 2024 and close at 5:00 pm (Melbourne. ....

Melbourne , Victoria , Australia , New-zealand , United-states , Frederic-guerard , Linkedin , Lifesci-advisors , Exchange-commission , Biotechnology-companies , Opthea-limited , Retail-entitlement-offer

Opthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m¹)

14.06.2024 - Fully underwritten Retail Entitlement Offer to raise a further approximately A$55.9m (US$36.9m1) will open on 19 June 2024 and close at 5:00 pm (Melbourne time) on 10 July 2024 MELBOURNE, Australia and PRINCETON, N.J., June 13, 2024 (GLOBE . ....

United-states , New-zealand , Melbourne , Victoria , Australia , Frederic-guerard , Exchange-commission , Biotechnology-companies , Linkedin , Lifesci-advisors , Institutional-entitlement-offer , Entitlement-offer

Opthea Announces Placement and Partially Underwritten

Opthea Announces Placement and Partially Underwritten
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Australia , United-states , New-zealand , Melbourne , Victoria , American , Frederic-guerard , Fred-guerard , Vegfd-research , Opthea-limited , Bell-potter-securities , Investment-in-biotechnology-companies

Capricor Advances in DMD Therapy With Positive Study Data - Hims & Hers Health (NYSE:HIMS), Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology firm focused on innovative therapies for rare diseases, has announced favorable three-year results from the ongoing HOPE-2 open-label extension (OLE) study on CAP-1002 for Duchenne muscular dystrophy. ....

United-states , Cincinnati , Ohio , Cincinnati-children-hospital-medical-center , Hims-hers-health , Cincinnati-children , Hospital-medical-center , Biologics-license-application , Market-prospects , Mordor-intelligence , Zacks-rank

CHECKPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating Checkpoint Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

CHECKPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating Checkpoint Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New-york , United-states , California , South-carolina , Brandon-walker , Bragar-eagel-squire , Marion-passmore , Drug-administration , Nasdaq , Checkpoint-therapeutics-inc , Checkpoint-therapeutics , Class-period